Poxel
Research integrated pharmaceutical company that develops products for metabolic diseases.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $50.0m | Post IPO Debt | |
| Total Funding | 000k | ||
Omnes Capital(exited)
Bpifrance(exited)
Kreos Capital(exited)
Andera Partners(exited)
InnoBio(exited)
Crédit Agricole(exited)
BNP Paribas(exited)
CIC(exited)
IPF Partners(exited)
IRIS Capital Investment(exited)
Edmond de Rothschild Group(exited)
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1380 % | (64 %) | (74 %) | 97 % | (95 %) | 194 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (420 %) | 16 % | (91 %) | (454 %) | (157 %) | (3203 %) | (627 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (440 %) | 18 % | (97 %) | (468 %) | (177 %) | (4658 %) | (1771 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 74 % | 168 % | 430 % | 205 % | 2068 % | 1058 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.